Cure My Disease

Don't miss your cure!

 Log in / Sign up

Engineered immune cells show promise against Hard-to-Treat lymphoma

NCT ID NCT03568461

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This study tested a treatment called tisagenlecleucel, a type of CAR-T cell therapy, in 98 adults with follicular lymphoma that had come back or stopped responding to other treatments. The therapy works by reprogramming a patient's own immune cells to find and attack cancer cells. The main goal was to see how many patients had their cancer completely disappear after treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

follicular lymphoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FOLLICULAR LYMPHOMA

Contacts and locations

Locations

  • City of Hope National Medical Center

    Duarte, California, 91010 3000, United States

  • H Lee Moffitt Cancer Center and Research Institute

    Tampa, Florida, 33612, United States

  • MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Michigan Med University of Michigan

    Ann Arbor, Michigan, 48109 5271, United States

  • Novartis Investigative Site

    Camperdown, New South Wales, 2050, Australia

  • Novartis Investigative Site

    Melbourne, Victoria, 3000, Australia

  • Novartis Investigative Site

    Herston, QLD 4006, Australia

  • Novartis Investigative Site

    Linz, 4020, Austria

  • Novartis Investigative Site

    Ghent, 9000, Belgium

  • Novartis Investigative Site

    Paris, 75475, France

  • Novartis Investigative Site

    Pierre-Bénite, 69495, France

  • Novartis Investigative Site

    Munich, Bavaria, 81377, Germany

  • Novartis Investigative Site

    Cologne, North Rhine-Westphalia, 50937, Germany

  • Novartis Investigative Site

    Ulm, 89081, Germany

  • Novartis Investigative Site

    Bologna, BO, 40138, Italy

  • Novartis Investigative Site

    Milan, MI, 20132, Italy

  • Novartis Investigative Site

    Sapporo, Hokkaido, 060-8648, Japan

  • Novartis Investigative Site

    Sendai, Miyagi, 9808574, Japan

  • Novartis Investigative Site

    Fukuoka, 8128582, Japan

  • Novartis Investigative Site

    Amsterdam, North Holland, 1081 HV, Netherlands

  • Novartis Investigative Site

    Oslo, Norway, 0310, Norway

  • Novartis Investigative Site

    Madrid, 28041, Spain

  • Novartis Investigative Site

    Seville, 41013, Spain

  • Novartis Investigative Site

    Birmingham, West Midlands, B15 2TH, United Kingdom

  • Novartis Investigative Site

    London, SE5 9RS, United Kingdom

  • Oregon Health Sciences University

    Portland, Oregon, 97239, United States

  • UCSF Medical Center

    San Francisco, California, 94143, United States

  • Uni of Chi Medi Ctr Hema and Onco

    Chicago, Illinois, 60637, United States

  • Univ of Kansas Hosp and Med Ctr

    Kansas City, Kansas, 66160, United States

  • University of Pennsylvania Clinical

    Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.